Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function

Pediatrics

Volumn 127, Issue 3, 2011, Pages

  Tan, Swee Thong ^a,b,c   Itinteang, Tinte ^a,b   Leadbitter, Philip ^a  

^a HUTT HOSPITAL   (New Zealand)

^b Gillies McIndoe Research Institute   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

blocker; Angiotensin; Hemangioma; Infantile; Involution; Propranolol; Renin; Treatment

Indexed keywords

BILIRUBIN; LIVER ENZYME; PROPRANOLOL;

APNEA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD FLOW; CASE REPORT; DEVELOPMENTAL DISORDER; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIUM; HEPATOMEGALY; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFANT; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER HEMANGIOMA; LOW DRUG DOSE; MALE; MESODERM; NEONATAL WEIGHT LOSS; NEURAL CREST CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS BRADYCARDIA; SKIN HEMANGIOMA; ULTRASOUND;

ADRENERGIC BETA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEMANGIOMA; HUMANS; INFANT, NEWBORN; LIVER; LIVER NEOPLASMS; MALE; PROPRANOLOL; SKIN NEOPLASMS;

EID: 79952208287     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1703     Document Type: Article

References (32)

1. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. The Guidelines of care for hemangiomas of infancy. American Academy of Dermatology, Guidelines/Outcomes Committee. J Am Acad Dermatol. 1997;37(4):631-637
2. Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg. 2000;106(3):529-537
3. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412-419
4. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RAB. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(6):2357-2364 (Pubitemid 24177146)
5. Waner M, North PE, Scherer KA, Frieden IJ, Waner A, Mihm MC Jr. The nonrandom distribution of facial hemangiomas. Arch Dermatol. 2003;139(7):869-875 (Pubitemid 36898921)
6. Metry DW, Hawrot A, Altman C, Frieden IJ. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol. 2004;140(5):591-596 (Pubitemid 38668967)
7. Horii KA, Drolet BA, Baselga E, et al; Hemangioma Investigator Group. Risk of hepatic hemangiomas in infants with large hemangiomas. Arch Dermatol. 2010;146(2):201-203
8. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341(3):173-181 (Pubitemid 29325746)
9. Chang LC, Haggstrom AN, Drolet BA, et al; Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367
10. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol. 1997;14(3):173-179 (Pubitemid 27255859)
11. Tan B, Leadbitter P, Auburn N, Tan ST. Steroid therapy for problematic proliferating haemangioma. N Z Med J. 2010; In press
12. Gangopadhyay A, Sinha C, Gopal S, Gupta D, Sahoo S, Ahmad M. Role of steroid in childhood haemangioma: a 10 years review. Int Surg. 1997;82(1):49-51 (Pubitemid 27243666)
13. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651 (Pubitemid 351831393)
14. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3). Available at: www.pediatrics.org/cgi/content/full/124/3/e423
15. Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G, Garabedian EN. Role of propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol. 2009;73(8):1168-1172
16. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119(10):2051- 2054
17. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162(2):466-468
18. Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2010; In press. doi:10.1016/j.bjps. 2010.06.010
19. Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg. 1967;39(1):76-83
20. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185-189 (Pubitemid 30489216)
21. Edgerton MT. The treatment of hemangiomas: with special reference to the role of steroid therapy. Ann Surg. 1976;183(5):517-530
22. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72(3):351-357
23. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-1213 (Pubitemid 32847844)
24. Fawcett SL, Grant I, Hall PN, Kelsall AWR, Nicholson JC. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg. 2004;57(2):168-171 (Pubitemid 38239893)
25. Wharton S, Soueid A, Nishikawa H, Sridhar A. Endangering cutaneous infantile hemangioma treated with vincristine: a case report. Eur J Plast Surg. 2009;32(3):157-161
26. Honey M, Chamberlain DA, Howard J. The effect of beta-sympathetic blockade on arterial oxygen saturation in Fallot's tetralogy. Circulation. 1964;30:501-510
27. Cherian G, Brockington I, Shah P, Oakley C, Goodwin J. Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy. Br Med J. 1966;1(5492):895-898
28. Siegfried EC, Keenan WJ, Al-Jureidini S, Leaute-Labreze C, de la Roque ED, Taieb A. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359(26):2846-2847
29. Itinteang T, Brasch HD, Tan ST, Day DJ. Expression of components of the reninangiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesth Surg. 2010; In press. doi:10.1016/j.bjps. 2010.08.039
30. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137(5):559-570 (Pubitemid 32458438)
31. Itinteang T, Tan ST, Brasch H, Day DJ. Haemogenic endothelium in infantile haemangioma. J Clin Pathol. 2010;63(11):982-986
32. Itinteang T, Tan ST, Brasch H, Day DJ. Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma. J Clin Pathol. 2010;63(9):771-776